A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy

This study is an open-label, single center, and a dose-escalating phase I study to determine the maximal tolerated dose and the recommended dose of S-1 combined with irinotecan/oxaliplatin in patients with unresectable or metastatic colorectal or gastric carcinoma.

本研究为一项开放标签、单中心、剂量爬坡型I期临床试验，旨在明确S-1联合伊立替康/奥沙利铂治疗不可切除或转移性结直肠癌或胃癌患者的最大耐受剂量与推荐剂量。